{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:14:37Z","timestamp":1790396077013,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","award":["021606 VK KG onderzoeksfonds, R0003521 Cure-I Hus BetaalbaarBeter"],"award-info":[{"award-number":["021606 VK KG onderzoeksfonds, R0003521 Cure-I Hus BetaalbaarBeter"]}],"id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>With the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS). In view of the high costs, actual needs of the drug, and increasing evidence in literature, aHUS patients can be treated according to a restrictive eculizumab regimen. We retrospectively analyzed the pharmacokinetic and dynamic parameters of eculizumab in one patient in time, emphasizing various factors which could be taken into account during tapering of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>A nowadays 18-year-old male with a severe, frequently relapsing form of atypical HUS due to a hybrid CFH\/CFHR1 gene in combination with the homozygous factor H haplotype, required chronic plasma therapy (PT), including periods with plasma infusion, from the age of onset at 5 months until initiation of eculizumab at the age of 11 years. A mild but stable chronic kidney disease (CKD) and 9 years of disease remission enabled prolongation of eculizumab interval. At the age of 15 years, a sudden yet multifactorial progression of chronic kidney disease (CKD) was observed, without any signs of disease recurrence. However, an acquired glomerulocystic disease, a reduced left kidney function, and abnormal abdominal venous system of unknown etiology were found. In addition, after an aHUS relapse, an unexpected increase in intra-patient variability of eculizumab concentrations was seen. Retrospective pharmacokinetic analysis revealed a change in eculizumab clearance, associated with a simultaneous increase in proteinuria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>High intra-patient variability of eculizumab pharmacokinetics were observed over time, emphasizing the necessity for adequate and continuous therapeutic drug monitoring in aHUS patients. Eculizumab serum trough levels together with complement activation markers (CH50) should be frequently assessed, especially during tapering of drug therapy and\/or changing clinical conditions in the patient. In addition, an increase in proteinuria could result in urinary eculizumab loss, indicating that urinary monitoring of eculizumab may be important in aHUS patients with an unexplained decline in serum concentrations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2020.612706","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T04:17:00Z","timestamp":1610684220000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient"],"prefix":"10.3389","volume":"11","author":[{"given":"Romy N.","family":"Bouwmeester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendy","family":"Ter Avest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kioa L.","family":"Wijnsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Duineveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena B.","family":"Volokhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus P. W. J.","family":"Van Den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F. M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C. A. J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"B2","article-title":"A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome","volume":"70","author":"Westra","year":"2012","journal-title":"Neth J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.04.008","article-title":"Factor H-related proteins determine complement-activating surfaces","volume":"36","author":"Jozsi","year":"2015","journal-title":"Trends Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx196","article-title":"Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome","volume":"33","author":"Wijnsma","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/humu.9408","article-title":"De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome","volume":"27","author":"Heinen","year":"2006","journal-title":"Hum Mutat"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1371\/journal.pmed.0030431","article-title":"Atypical haemolytic uraemic syndrome associated with a hybrid complement gene","volume":"3","author":"Venables","year":"2006","journal-title":"PLoS Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11825-018-0216-0","article-title":"The genetics of atypical hemolytic uremic syndrome","volume":"30","author":"Feitz","year":"2018","journal-title":"Med Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2817-4","article-title":"An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome","volume":"29","author":"Johnson","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.686","article-title":"Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment","volume":"102","author":"Volokhina","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab","volume":"58","author":"Wijnsma","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jim.2018.06.010","article-title":"The impact of eculizumab on routine complement assays","volume":"460","author":"Willrich","year":"2018","journal-title":"J\u00a0Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddg363","article-title":"Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease","volume":"12","author":"Caprioli","year":"2003","journal-title":"Hum Mol Genet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical\u00a0features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-013-2591-8","article-title":"Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH\/CFHR1 hybrid gene","volume":"29","author":"Roman-Ortiz","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00467-017-3649-9","article-title":"Acquired cystic kidney disease: an under-recognized condition in children with end-stage renal disease","volume":"33","author":"Chan","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(02)00254-7","article-title":"Functional characterization of the lectin pathway of complement in human serum","volume":"39","author":"Roos","year":"2003","journal-title":"Mol Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2003.01153.x","article-title":"Urinary excretion of complement\u00a0C3d in patients with renal diseases","volume":"33","author":"Branten","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12426","article-title":"Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission","volume":"181","author":"Volokhina","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.05.221","article-title":"An international serum standard for application in assays to detect human complement activation products","volume":"56","author":"Bergseth","year":"2013","journal-title":"Mol Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0406-y","article-title":"The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment","volume":"17","author":"van den Heuvel","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2014.11.003","article-title":"Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn","volume":"220","author":"Hallstensen","year":"2015","journal-title":"Immunobiology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs029","article-title":"Urinary albumin to protein ratio: more of the same or making a difference","volume":"27","author":"Ellam","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.121","article-title":"Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease","volume":"53","author":"Roberts","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2011-300685","article-title":"Puberty is associated with increased deterioration of renal function in patients with CKD: data from the ItalKid Project","volume":"97","author":"Ardissino","year":"2012","journal-title":"Arch Dis Child"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.612706\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T04:17:03Z","timestamp":1610684223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.612706\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2020.612706"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.612706","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"article-number":"612706"}}